Advances in proteomic study of cardiac amyloidosis: progress and potential

References

• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 1924-1933;29(14):2011.
   Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221–224.
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–350.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91–102.
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113–122.
   PubMed Web of Science ®Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Albertini R, Di Fonzo A, et al. Biochemical markers in early diagnosis and management of systemic amyloidoses. Clin Chem Lab Med. 2014;52(11):1517–1531.
   PubMed Web of Science ®Google Scholar
• Merlini G, Lousada I, Ando Y, et al. Rationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016. Epub ahead of print. DOI:10.1038/leu.2016.191
   PubMedGoogle Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Nezafat R. Cardiovascular magnetic resonance visualization of cardiac amyloid infiltration: challenges and opportunities. Circulation. 2015;132(16):1525–1527.
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss DT, Murphy C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol. 1994;45(2):171–176.
   PubMed Web of Science ®Google Scholar
• Takayama F, Miyazaki S, Morita T, et al. Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Kidney Int Suppl. 2001;78:S172–S176.
   PubMed Web of Science ®Google Scholar
• Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med. 2012;366(24):2276–2283.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–172.
   PubMed Web of Science ®Google Scholar
• Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
   PubMedGoogle Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Schönland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11(3):257–262.
   PubMed Web of Science ®Google Scholar
• Valleix S, Verona G, Jourde-Chiche N, et al. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun. 2016;7:10353.
   PubMed Web of Science ®Google Scholar
• Steiner I, Hájková P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol. 2006;15(5):287–290.
   PubMed Web of Science ®Google Scholar
• Larsen BT, Mereuta OM, Dasari S, et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2016;68(5):648–656.
   PubMed Web of Science ®Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–5130.
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492–1495.
   PubMed Web of Science ®Google Scholar
• Perfetti V, Palladini G, Casarini S, et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119(1):144–150.
   PubMed Web of Science ®Google Scholar
• Dasari S, Theis JD, Vrana JA, et al. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res. 2015;14(4):1957–1967.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–528.
   PubMed Web of Science ®Google Scholar
• Maury CP, Baumann M. Isolation and characterization of cardiac amyloid in familial amyloid polyneuropathy type IV (Finnish): relation of the amyloid protein to variant gelsolin. Biochim Biophys Acta. 1990;1096(1):84–86.
   PubMed Web of Science ®Google Scholar
• Bergstrom J, Murphy CL, Weiss DT, et al. Two different types of amyloid deposits–apolipoprotein A-IV and transthyretin–in a patient with systemic amyloidosis. Lab Invest. 2004;84(8):981–988.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300.
   PubMed Web of Science ®Google Scholar
• Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs. 2014;23(9):1239–1251.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Gertz MA. Newer therapies for amyloid cardiomyopathy. Curr Heart Fail Rep. 2016. Epub ahead of print. DOI: 10.1007/s11897-016-0300-1.
   PubMedGoogle Scholar
• Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2016. Epub ahead of print. DOI: 10.1093/ndt/gfw305.
   PubMedGoogle Scholar
• Theis JD, Dasari S, Vrana JA, et al. Shotgun proteomics-based clinical testing for diagnosis and classification of amyloidosis. J Mass Spectrom. 2013;48(10):1067–1077.
   PubMed Web of Science ®Google Scholar
• Seldin DC, Sanchorawala V. Amyloidomics comes of age. Blood. 1795-1796;119(8):2012.
   Google Scholar
• Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid. 2011;18(4):177–182.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics. 2008;7(8):1570–1583.
   PubMed Web of Science ®Google Scholar
• Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48–62.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 1844-1847;119(8):2012.
   Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–4959.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99(7):1239–1247.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013;22(3):189–194.
   PubMed Web of Science ®Google Scholar
• Satoskar AA, Efebera Y, Hasan A, et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol. 1685-1690;35(11):2011.
   Google Scholar
• Fernandez de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;125(14):2239–2244.
   PubMed Web of Science ®Google Scholar
• Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014;123(10):1479–1482.
   PubMed Web of Science ®Google Scholar
• Nasr SH, Dogan A, Larsen CP. Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol. 2015;10(11):2084–2093.
   PubMed Web of Science ®Google Scholar
• Dasari S, Amin MS, Kurtin PJ, et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int. 2016;S0085-2538(16):30130–30132.
   Google Scholar
• Nasr SH, Dasari S, Hasadsri L, et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol. 2016. Epub ahead of print. DOI: 10.1681/ASN.2015111228.
   PubMedGoogle Scholar
• Dasari S, Theis JD, Vrana JA, et al. Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res. 2014;13(5):2352–2358.
   PubMed Web of Science ®Google Scholar
• Bodi K, Prokaeva T, Spencer B, et al. AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid. 2009;16(1):1–8.
   PubMed Web of Science ®Google Scholar
• Kourelis T, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens. J Clin Oncol. 2014;32(5s):abstr 8605.
   Google Scholar
• Kourelis T, Dasari S, Kurtin PJ, et al. Immunoglobulin variable region family usage and outcomes of patients with systemic light chain amyloidosis. Blood. 2014;124(3402). http://www.bloodjournal.org/content/124/21/3402.
   Google Scholar
• Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82(2):226–234.
   PubMed Web of Science ®Google Scholar
• Valentini V, Lavatelli F, Obici L, et al. Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid. 2011;18(Suppl 1):61–63.
   PubMed Web of Science ®Google Scholar
• Catherman AD, Skinner OS, Kelleher NL. Top down proteomics: facts and perspectives. Biochem Biophys Res Commun. 2014;445(4):683–693.
   PubMed Web of Science ®Google Scholar
• Enqvist S, Sletten K, Westermark P. Fibril protein fragmentation pattern in systemic AL-amyloidosis. J Pathol. 2009;219(4):473–480.
   PubMed Web of Science ®Google Scholar
• Klimtchuk ES, Gursky O, Patel RS, et al. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry. 2010;49(45):9848–9857.
   PubMed Web of Science ®Google Scholar
• Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990;74(1):65–69.
   PubMed Web of Science ®Google Scholar
• Souillac PO, Uversky VN, Millett IS, et al. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J Biol Chem. 2002;277(15):12657–12665.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Brambilla F, Valentini V, et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta. 2011;1814(3):409–419.
   PubMed Web of Science ®Google Scholar
• Lim A, Wally J, Walsh MT, et al. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem. 2001;295(1):45–56.
   PubMed Web of Science ®Google Scholar
• Connors LH, Jiang Y, Budnik M, et al. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry. 2007;46(49):14259–14271.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253–261.
   PubMed Web of Science ®Google Scholar
• Pilebro B, Suhr OB, Näslund U, et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17–24.
   PubMed Web of Science ®Google Scholar
• Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20(3):142–150.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Theberge R, Karbassi JA, et al. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry. Anal Chem. 1990-1998;79(5):2007.
   Google Scholar
• Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7(10):1337–1349.
   PubMed Web of Science ®Google Scholar
• Mangione PP, Porcari R, Gillmore JD, et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A. 2014;111(4):1539–1544.
   PubMed Web of Science ®Google Scholar
• Ihse E, Suhr OB, Hellman U, et al. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl). 2011;89(2):171–180.
   PubMed Web of Science ®Google Scholar
• Tasaki M, Ueda M, Obayashi K, et al. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol. 2013;170(1):69–74.
   PubMed Web of Science ®Google Scholar
• Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin val30Met familial amyloid polyneuropathy. J Neurol Sci. 2009;287(1–2):178–184.
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327.
   PubMed Web of Science ®Google Scholar
• Oshima T, Kawahara S, Ueda M, et al. Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation. J Neurol Neurosurg Psychiatry. 2014;85(7):740–746.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst. 2008;4(1):42–52.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D et al.. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res. 2013;12(12):5642–5655.
   PubMed Web of Science ®Google Scholar
• Greene MJ, Sam F, Soo Hoo PT, et al. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol. 2011;178(1):61–68.
   PubMed Web of Science ®Google Scholar
• Da Costa G, Ribeiro-Silva C, Ribeiro R, et al. Transthyretin amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease. PLoS One. 2015;10(7):e0125392.
   Web of Science ®Google Scholar
• Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A. 1994;91(12):5602–5606.
   PubMed Web of Science ®Google Scholar
• Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A. 1995;92(10):4299–4303.
   PubMed Web of Science ®Google Scholar
• Sapp V, Jain M, Liao R. Viewing extrinsic proteotoxic stress through the lens of amyloid cardiomyopathy. Physiology (Bethesda). 2016;31(4):294–299.
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854–3858.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212.
   PubMed Web of Science ®Google Scholar
• Olzscha H, Schermann SM, Woerner AC, et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell. 2011;144(1):67–78.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Imperlini E, Orrù S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. Faseb J. 2015;29(11):4614–4628.
   PubMed Web of Science ®Google Scholar
• Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction–Alzheimer’s disease of the heart? N Engl J Med. 2013;368(5):455–464.
   PubMed Web of Science ®Google Scholar
• Del Monte F, Agnetti G. Protein post-translational modifications and misfolding: new concepts in heart failure. Proteomics Clin Appl. 2014;8(7–8):534–542.
   PubMed Web of Science ®Google Scholar
• Subramanian K, Gianni D, Balla C, et al. Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1199–1214.
   PubMed Web of Science ®Google Scholar
• Gianni D, Li A, Tesco G, et al. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation. 2010;121(10):1216–1226.
   PubMed Web of Science ®Google Scholar
• Diomede L, Rognoni P, Lavatelli F, et al. A caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014;123(23):3543–3552.
   PubMed Web of Science ®Google Scholar
• Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013;305(1):H95–H103.
   PubMed Web of Science ®Google Scholar
• Kim S, Bandeira N, Pevzner PA. Spectral profiles, a novel representation of tandem mass spectra and their applications for de novo peptide sequencing and identification. Mol Cell Proteomics. 2009;8(6):1391–1400.
   PubMed Web of Science ®Google Scholar
• Olson MT, Epstein JA, Yergey AL. De novo peptide sequencing using exhaustive enumeration of peptide composition. J Am Soc Mass Spectrom. 2006;17(8):1041–1049.
   PubMed Web of Science ®Google Scholar
• Mo L, Dutta D, Wan Y, et al. MSNovo: a dynamic programming algorithm for de novo peptide sequencing via tandem mass spectrometry. Anal Chem. 2007;79(13):4870–4878.
   PubMed Web of Science ®Google Scholar
• Gustafsson OJ, Arentz G, Hoffmann P. Proteomic developments in the analysis of formalin-fixed tissue. Biochim Biophys Acta. 2015;1854(6):559–580.
   PubMed Web of Science ®Google Scholar
• Bergström J, Murphy C, Eulitz M, et al. Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun. 2001;285(4):903–908.
   PubMed Web of Science ®Google Scholar
• de Sousa MM, Vital C, Ostler D, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol. 2000;156(6):1911–1917.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Gilbertson JA, Rendell N, et al. Two types of amyloid in a single heart. Blood. 2014;124(19):3025–3027.
   PubMed Web of Science ®Google Scholar
• Casadonte R, Kriegsmann M, Deininger SO, et al. Imaging mass spectrometry analysis of renal amyloidosis biopsies reveals protein co-localization with amyloid deposits. Anal Bioanal Chem. 2015;407(18):5323–5331.
   PubMed Web of Science ®Google Scholar
• Winter M, Tholey A, Krüger S, et al. MALDI-mass spectrometry imaging identifies vitronectin as a common constituent of amyloid deposits. J Histochem Cytochem. 2015;63(10):772–779.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Ito M, Nirasawa T, et al. Topologies of amyloidogenic proteins in congo red-positive sliced sections of formalin-fixed paraffin embedded tissues by MALDI-MS imaging coupled with on-tissue tryptic digestion. Clin Biochem. 2013;46(15):1595–1600.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Bensimon A, Collins BC, et al. Applications and developments in targeted proteomics: from SRM to DIA/SWATH. Proteomics. 2016;16(15–16):2065–2067.
   PubMed Web of Science ®Google Scholar
• Shao S, Guo T, Gross V, et al. Reproducible tissue homogenization and protein extraction for quantitative proteomics using micropestle-assisted pressure-cycling technology. J Proteome Res. 2016;15(6):1821–1829.
   PubMed Web of Science ®Google Scholar
• Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111.016717.
   PubMed Web of Science ®Google Scholar
• Keller A, Bader SL, Kusebauch U, et al. Opening a SWATH window on posttranslational modifications: automated pursuit of modified peptides. Mol Cell Proteomics. 2016;15(3):1151–1163.
   PubMed Web of Science ®Google Scholar
• Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry. 2013;52(22):3797–3806.
   PubMed Web of Science ®Google Scholar